OBJECTIVE: Depression and substance use, the most common comorbidities with HIV, are both associated with poor treatment adherence. Injection drug users comprise a substantial portion of individuals with HIV in the United States and globally. The present study tested cognitive behavioral therapy for adherence and depression (CBT-AD) in patients with HIV and depression in active substance abuse treatment for injection drug use. METHOD: This is a 2-arm, randomized controlled trial (N = 89) comparing CBT-AD with enhanced treatment as usual (ETAU). Analyses were conducted for two time-frames: (a) baseline to post-treatment and (b) post-treatment to follow-up at 3 and 6 months after intervention discontinuation. RESULTS: At post-treatment, the CBT-AD condition showed significantly greater improvement than ETAU in MEMS (electronic pill cap) based adherence, γslope = 0.8873, t(86) = 2.38, p = .02; dGMA-raw = 0.64, and depression, assessed by blinded assessor: Mongomery-Asberg Depression Rating Scale, F(1, 79) = 6.52, p < .01, d = 0.55; clinical global impression, F(1, 79) = 14.77, p < .001, d = 0.85. After treatment discontinuation, depression gains were maintained, but adherence gains were not. Viral load did not differ across condition; however, the CBT-AD condition had significant improvements in CD4 cell counts over time compared with ETAU, γslope = 2.09, t(76) = 2.20, p = .03, dGMA-raw = 0.60. CONCLUSIONS: In patients managing multiple challenges including HIV, depression, substance dependence, and adherence, CBT-AD is a useful way to integrate treatment of depression with an adherence intervention. Continued adherence counseling is likely needed, however, to maintain or augment adherence gains in this population.
RCT Entities:
OBJECTIVE:Depression and substance use, the most common comorbidities with HIV, are both associated with poor treatment adherence. Injection drug users comprise a substantial portion of individuals with HIV in the United States and globally. The present study tested cognitive behavioral therapy for adherence and depression (CBT-AD) in patients with HIV and depression in active substance abuse treatment for injection drug use. METHOD: This is a 2-arm, randomized controlled trial (N = 89) comparing CBT-AD with enhanced treatment as usual (ETAU). Analyses were conducted for two time-frames: (a) baseline to post-treatment and (b) post-treatment to follow-up at 3 and 6 months after intervention discontinuation. RESULTS: At post-treatment, the CBT-AD condition showed significantly greater improvement than ETAU in MEMS (electronic pill cap) based adherence, γslope = 0.8873, t(86) = 2.38, p = .02; dGMA-raw = 0.64, and depression, assessed by blinded assessor: Mongomery-Asberg Depression Rating Scale, F(1, 79) = 6.52, p < .01, d = 0.55; clinical global impression, F(1, 79) = 14.77, p < .001, d = 0.85. After treatment discontinuation, depression gains were maintained, but adherence gains were not. Viral load did not differ across condition; however, the CBT-AD condition had significant improvements in CD4 cell counts over time compared with ETAU, γslope = 2.09, t(76) = 2.20, p = .03, dGMA-raw = 0.60. CONCLUSIONS: In patients managing multiple challenges including HIV, depression, substance dependence, and adherence, CBT-AD is a useful way to integrate treatment of depression with an adherence intervention. Continued adherence counseling is likely needed, however, to maintain or augment adherence gains in this population.
Authors: Honghu Liu; Loren G Miller; Ron D Hays; Carol E Golin; Tongtong Wu; Neil S Wenger; Andrew H Kaplan Journal: J Acquir Immune Defic Syndr Date: 2006-03 Impact factor: 3.731
Authors: Steven A Safren; Conall O'Cleirigh; Judy Y Tan; Sudha R Raminani; Laura C Reilly; Michael W Otto; Kenneth H Mayer Journal: Health Psychol Date: 2009-01 Impact factor: 4.267
Authors: Glenn J Wagner; Bonnie Ghosh-Dastidar; Eric Robinson; Victoria K Ngo; Peter Glick; Barbara Mukasa; Seggane Musisi; Dickens Akena Journal: AIDS Behav Date: 2017-06
Authors: Bryan Hartzler; Julia C Dombrowski; Jason R Williams; Heidi M Crane; Joseph J Eron; Elvin H Geng; Christopher Mathews; Kenneth H Mayer; Richard D Moore; Michael J Mugavero; Sonia Napravnik; Benigno Rodriguez; Dennis M Donovan Journal: AIDS Behav Date: 2018-03
Authors: Brent A Moore; Marc I Rosen; Yan Wang; Jie Shen; Karen Ablondi; Anna Sullivan; Mario Guerrero; Lisa Siqueiros; Eric S Daar; Honghu Liu Journal: AIDS Behav Date: 2015-06
Authors: Joseph A Delaney; Robin M Nance; Bridget M Whitney; Frederick L Altice; Xinyuan Dong; Maria Esther Perez Trejo; Mika Matsuzaki; Faye S Taxman; Geetanjali Chander; Irene Kuo; Rob Fredericksen; Lauren N Strand; Joseph J Eron; Elvin Geng; Mari M Kitahata; William C Mathews; Kenneth Mayer; Richard D Moore; Michael S Saag; Sandra Springer; Redonna Chandler; Shoshana Kahana; Heidi M Crane Journal: J Acquir Immune Defic Syndr Date: 2018-11-01 Impact factor: 3.731
Authors: Bulent Turan; Whitney S Rice; Kaylee B Crockett; Mallory Johnson; Torsten B Neilands; Shericia N Ross; Mirjam-Colette Kempf; Deborah Konkle-Parker; Gina Wingood; Phyllis C Tien; Mardge Cohen; Tracey E Wilson; Carmen H Logie; Oluwakemi Sosanya; Michael Plankey; Elizabeth Golub; Adaora A Adimora; Carrigan Parish; Sheri D Weiser; Janet M Turan Journal: AIDS Date: 2019-03-01 Impact factor: 4.177